Ryan C Fields

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/563269/publications.pdf

Version: 2024-02-01

337 papers	12,348 citations	30070 54 h-index	42399 92 g-index
341 all docs	341 docs citations	341 times ranked	16709 citing authors

#	Article	IF	Citations
1	Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. Lancet Oncology, The, 2016, 17, 651-662.	10.7	557
2	Tissue-Resident Macrophages in Pancreatic Ductal Adenocarcinoma Originate from Embryonic Hematopoiesis and Promote Tumor Progression. Immunity, 2017, 47, 323-338.e6.	14.3	499
3	Driver Fusions and Their Implications in the Development and Treatment of Human Cancers. Cell Reports, 2018, 23, 227-238.e3.	6.4	407
4	Targeting both tumour-associated CXCR2⁺ neutrophils and CCR2⁺ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma. Gut, 2018, 67, 1112-1123.	12.1	334
5	The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution. Cell, 2020, 181, 236-249.	28.9	334
6	Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 367-402.	4.9	326
7	Dendritic Cell Paucity Leads to Dysfunctional Immune Surveillance in Pancreatic Cancer. Cancer Cell, 2020, 37, 289-307.e9.	16.8	252
8	Regional Lymphadenectomy Is Indicated in the Surgical Treatment of Pancreatic Neuroendocrine Tumors (PNETs). Annals of Surgery, 2014, 259, 197-203.	4.2	213
9	Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 450-473.	4.9	203
10	Tumor-on-a-chip platform to investigate progression and drug sensitivity in cell lines and patient-derived organoids. Lab on A Chip, 2018, 18, 3687-3702.	6.0	193
11	Surgical Resection of the Primary Tumor is Associated with Increased Long-Term Survival in Patients with Stage IV Breast Cancer after Controlling for Site of Metastasis. Annals of Surgical Oncology, 2007, 14, 3345-3351.	1.5	191
12	NCCN GuidelinesÂ® Insights: Melanoma: Cutaneous, Version 2.2021. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 364-376.	4.9	167
13	Recurrence and Survival in Patients Undergoing Sentinel Lymph Node Biopsy for Merkel Cell Carcinoma: Analysis of 153 Patients from a Single Institution. Annals of Surgical Oncology, 2011, 18, 2529-2537.	1.5	164
14	Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance. Nature Communications, 2018, 9, 1250.	12.8	151
15	Five Hundred Patients With Merkel Cell Carcinoma Evaluated at a Single Institution. Annals of Surgery, 2011, 254, 465-475.	4.2	148
16	Agonism of CD11b reprograms innate immunity to sensitize pancreatic cancer to immunotherapies. Science Translational Medicine, 2019, 11, .	12.4	148
17	Rates and Patterns of Recurrence after Curative Intent Resection for Gastric Cancer: A United States Multi-Institutional Analysis. Journal of the American College of Surgeons, 2014, 219, 664-675.	0.5	139
18	Transplantation Versus Resection for Hilar Cholangiocarcinoma. Annals of Surgery, 2018, 267, 797-805.	4.2	137

#	Article	IF	Citations
19	Complete Response to Neoadjuvant Chemoradiation for Rectal Cancer Does Not Influence Survival. Annals of Surgical Oncology, 2001, 8, 801-806.	1.5	122
20	Early Posttransplant Inflammation Promotes the Development of Alloimmunity and Chronic Human Lung Allograft Rejection. Transplantation, 2007, 83, 150-158.	1.0	119
21	Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer. Annals of Surgery, 2019, 270, 400-413.	4.2	113
22	Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma. JAMA Oncology, 2020, 6, 60.	7.1	112
23	Metabolic syndrome, metabolic comorbid conditions and risk of early-onset colorectal cancer. Gut, 2021, 70, 1147-1154.	12.1	109
24	Oncologic Outcomes of Sporadic, Neurofibromatosis-Associated, and Radiation-Induced Malignant Peripheral Nerve Sheath Tumors. Annals of Surgical Oncology, 2013, 20, 66-72.	1.5	104
25	Nomograms to Predict Recurrence-Free and Overall Survival After Curative Resection of Adrenocortical Carcinoma. JAMA Surgery, 2016, 151, 365.	4.3	102
26	Development of resistance to FAK inhibition in pancreatic cancer is linked to stromal depletion. Gut, 2020, 69, 122-132.	12.1	89
27	Dermatofibrosarcoma protuberans (DFSP): Predictors of Recurrence and the Use of Systemic Therapy. Annals of Surgical Oncology, 2011, 18, 328-336.	1.5	88
28	Value of Intraoperative Neck Margin Analysis During Whipple for Pancreatic Adenocarcinoma. Annals of Surgery, 2014, 260, 494-503.	4.2	88
29	Recruitment of CCR2⁺tumor associated macrophage to sites of liver metastasis confers a poor prognosis in human colorectal cancer. OncoImmunology, 2018, 7, e1470729.	4.6	88
30	Prognostic Performance of Different Lymph Node Staging Systems After Curative Intent Resection for Gastric Adenocarcinoma. Annals of Surgery, 2015, 262, 991-998.	4.2	83
31	Long non-coding RNA RAMS11 promotes metastatic colorectal cancer progression. Nature Communications, 2020, 11, 2156.	12.8	83
32	Association of Preoperative Risk Factors With Malignancy in Pancreatic Mucinous Cystic Neoplasms. JAMA Surgery, 2017, 152, 19.	4.3	82
33	Recurrence after complete resection and selective use of adjuvant therapy for stage I through III Merkel cell carcinoma. Cancer, 2012, 118, 3311-3320.	4.1	81
34	NCCN Guidelines Insights: Melanoma, Version 3.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 945-958.	4.9	76
35	Adrenocortical Carcinoma: Impact of Surgical Margin Status on Long-Term Outcomes. Annals of Surgical Oncology, 2016, 23, 134-141.	1.5	76
36	Protease-Activated Receptor-2 Signaling Triggers Dendritic Cell Development. American Journal of Pathology, 2003, 162, 1817-1822.	3.8	74

#	Article	IF	Citations
37	Association of Optimal Time Interval to Re-resection for Incidental Gallbladder Cancer With Overall Survival. JAMA Surgery, 2017, 152, 143.	4.3	74
38	Up and down or side to side? A systematic review and meta-analysis examining the impact of incision on outcomes after abdominal surgery. American Journal of Surgery, 2013, 206, 400-409.	1.8	73
39	Number of Lymph Nodes Removed and Survival after Gastric Cancer Resection: An Analysis from the US Gastric Cancer Collaborative. Journal of the American College of Surgeons, 2015, 221, 291-299.	0.5	73
40	Outcomes of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A 13-Institution Study by the US Adrenocortical Carcinoma Group. Journal of the American College of Surgeons, 2016, 222, 480-490.	0.5	71
41	Effect of Perioperative Transfusion on Recurrence and Survival after Gastric Cancer Resection: A 7-Institution Analysis of 765 Patients from the US Gastric Cancer Collaborative. Journal of the American College of Surgeons, 2015, 221, 767-777.	0.5	70
42	Ablative Five-Fraction Stereotactic Body Radiation Therapy for Inoperable Pancreatic Cancer Using Online MR-Guided Adaptation. Advances in Radiation Oncology, 2021, 6, 100506.	1.2	70
43	Clonal Architectures and Driver Mutations in Metastatic Melanomas. PLoS ONE, 2014, 9, e111153.	2.5	69
44	A Novel Pathology-Based Preoperative Risk Score to Predict Locoregional Residual and Distant Disease and Survival for Incidental Gallbladder Cancer: A 10-Institution Study from the U.S. Extrahepatic Biliary Malignancy Consortium. Annals of Surgical Oncology, 2017, 24, 1343-1350.	1.5	68
45	Impact of body mass index on perioperative outcomes and survival after resection for gastric cancer. Journal of Surgical Research, 2015, 195, 74-82.	1.6	66
46	Rates and patterns of recurrence after curative intent resection for gallbladder cancer: a multi-institution analysis from the US Extra-hepatic Biliary Malignancy Consortium. Hpb, 2016, 18, 872-878.	0.3	66
47	Interaction of Postoperative Morbidity and Receipt of Adjuvant Therapy on Long-Term Survival After Resection for Gastric Adenocarcinoma: Results From the U.S. Gastric Cancer Collaborative. Annals of Surgical Oncology, 2016, 23, 2398-2408.	1.5	63
48	A Nomogram to Predict Overall Survival and Disease-Free Survival After Curative Resection of Gastric Adenocarcinoma. Annals of Surgical Oncology, 2015, 22, 1828-1835.	1.5	62
49	B cellâ€“Derived IL35 Drives STAT3-Dependent CD8+ T-cell Exclusion in Pancreatic Cancer. Cancer Immunology Research, 2020, 8, 292-308.	3.4	62
50	Conditional Survival after Surgical Resection of Gastric Cancer: A Multi-Institutional Analysis of the US Gastric Cancer Collaborative. Annals of Surgical Oncology, 2015, 22, 557-564.	1.5	61
51	Perihilar Cholangiocarcinoma: Number of Nodes Examined and Optimal Lymph Node Prognostic Scheme. Journal of the American College of Surgeons, 2016, 222, 750-759e2.	0.5	61
52	Loop Ileostomy Closure at an Ambulatory Surgery Facility. Diseases of the Colon and Rectum, 2003, 46, 486-490.	1.3	60
53	Induction of IL-10 Suppressors in Lung Transplant Patients by CD4+25+ Regulatory T Cells through CTLA-4 Signaling. Journal of Immunology, 2006, 177, 5631-5638.	0.8	60
54	Use of Endoscopic Ultrasound in the Preoperative Staging of Gastric Cancer: A Multi-Institutional Study of the US Gastric Cancer Collaborative. Journal of the American College of Surgeons, 2015, 220, 48-56.	0.5	58

#	Article	IF	Citations
55	Tumor-on-chip modeling of organ-specific cancer and metastasis. Advanced Drug Delivery Reviews, 2021, 175, 113798.	13.7	57
56	Treatment and outcomes of patients with primary breast sarcoma. American Journal of Surgery, 2008, 196, 559-561.	1.8	55
57	Utility of the Proximal Margin Frozen Section for Resection of Gastric Adenocarcinoma: A 7-Institution Study of the US Gastric Cancer Collaborative. Annals of Surgical Oncology, 2014, 21, 4202-4210.	1.5	55
58	Jaundice: an important, poorly recognized risk factor for diminished survival in patients with adenocarcinoma of the head of the pancreas. Hpb, 2014, 16, 150-156.	0.3	54
59	Utility of a multidisciplinary tumor board in the management of pancreatic and upper gastrointestinal diseases: an observational study. Hpb, 2017, 19, 133-139.	0.3	54
60	Noninvasive Determination of Melanoma Depth using a Handheld Photoacoustic Probe. Journal of Investigative Dermatology, 2017, 137, 1370-1372.	0.7	54
61	Prognostic Role of Lymph Node Positivity and Number of Lymph Nodes Needed for Accurately Staging Small-Bowel Neuroendocrine Tumors. JAMA Surgery, 2019, 154, 134.	4.3	54
62	A Novel Validated Recurrence Risk Score to Guide a Pragmatic Surveillance Strategy After Resection of Pancreatic Neuroendocrine Tumors. Annals of Surgery, 2019, 270, 422-433.	4.2	53
63	Elevated NLR in gallbladder cancer and cholangiocarcinoma â€“ making bad cancers even worse: results from the US Extrahepatic Biliary Malignancy Consortium. Hpb, 2016, 18, 950-957.	0.3	50
64	Racial Differences in Survival after Surgical Treatment for Melanoma. Annals of Surgical Oncology, 2011, 18, 2925-2936.	1.5	49
65	The Impact of Intraoperative Re-Resection of a Positive Bile Duct Margin on Clinical Outcomes for Hilar Cholangiocarcinoma. Annals of Surgical Oncology, 2018, 25, 1140-1149.	1.5	48
66	Defining Early Recurrence of Hilar Cholangiocarcinoma After Curativeâ€intent Surgery: A Multiâ€institutional Study from the US Extrahepatic Biliary Malignancy Consortium. World Journal of Surgery, 2018, 42, 2919-2929.	1.6	48
67	Left-Sided Pancreatic Cancer. Cancer Journal (Sudbury, Mass), 2012, 18, 562-570.	2.0	47
68	Impact of tumor size and nodal status on recurrence of nonfunctional pancreatic neuroendocrine tumors â‰¥2â€‰cm after curative resection: A multiâ€institutional study of 392 cases. Journal of Surgical Oncology, 2019, 120, 1071-1079.	1.7	47
69	Long-Term Endocrine and Exocrine Insufficiency After Pancreatectomy. Journal of Gastrointestinal Surgery, 2019, 23, 1604-1613.	1.7	47
70	Binocular Goggle Augmented Imaging and Navigation System provides real-time fluorescence image guidance for tumor resection and sentinel lymph node mapping. Scientific Reports, 2015, 5, 12117.	3.3	46
71	Is It Time to Abandon the 5-cm Margin Rule During Resection of Distal Gastric Adenocarcinoma? A Multi-Institution Study of the U.S. Gastric Cancer Collaborative. Annals of Surgical Oncology, 2015, 22, 1243-1251.	1.5	45
72	Precision delivery of RAS-inhibiting siRNA to KRAS driven cancer via peptide-based nanoparticles. Oncotarget, 2019, 10, 4761-4775.	1.8	45

#	Article	IF	Citations
73	Impact of Chemotherapy and External-Beam Radiation Therapy on Outcomes among Patients with Resected Gallbladder Cancer: A Multi-institutional Analysis. Annals of Surgical Oncology, 2016, 23, 2998-3008.	1.5	44
74	Pathologic and Prognostic Implications of Incidental versus Nonincidental Gallbladder Cancer: A 10-Institution Study from the United States Extrahepatic Biliary Malignancy Consortium. American Surgeon, 2017, 83, 679-686.	0.8	44
75	Cross Validation of the Monoclonal Antibody Das-1 in Identification of High-Risk Mucinous Pancreatic Cystic Lesions. Gastroenterology, 2019, 157, 720-730.e2.	1.3	44
76	Resection of Tumors of the Neck of the Pancreas with Venous Invasion: the â€œWhipple at the Splenic Artery (WATSA)â€•Procedure. Journal of Gastrointestinal Surgery, 2012, 16, 1048-1054.	1.7	42
77	Prognostic Implications of Lymph Node Status for Patients With Gallbladder Cancer: A Multi-Institutional Study. Annals of Surgical Oncology, 2016, 23, 3016-3023.	1.5	42
78	Outcomes after resection of cortisol-secreting adrenocortical carcinoma. American Journal of Surgery, 2016, 211, 1106-1113.	1.8	42
79	Curative Resection of Adrenocortical Carcinoma: Rates and Patterns of Postoperative Recurrence. Annals of Surgical Oncology, 2016, 23, 126-133.	1.5	42
80	The clonal evolution of metastatic colorectal cancer. Science Advances, 2020, 6, eaay9691.	10.3	41
81	Factors Associated With Recurrence and Survival in Lymph Nodeâ€“negative Gastric Adenocarcinoma. Annals of Surgery, 2015, 262, 999-1005.	4.2	40
82	Cytoreductive debulking surgery among patients with neuroendocrine liver metastasis: a multi-institutional analysis. Hpb, 2018, 20, 277-284.	0.3	39
83	Margin status and long-term prognosis of primary pancreatic neuroendocrine tumor after curative resection: Results from the US Neuroendocrine Tumor Study Group. Surgery, 2019, 165, 548-556.	1.9	39
84	Single institution results of radical antegrade modular pancreatosplenectomy for adenocarcinoma of the body and tail of pancreas in 78 patients. Journal of Hepato-Biliary-Pancreatic Sciences, 2016, 23, 432-441.	2.6	38
85	Lymphadenectomy for Adrenocortical Carcinoma: Is There a Therapeutic Benefit?. Annals of Surgical Oncology, 2016, 23, 708-713.	1.5	38
86	Curative Surgical Resection of Adrenocortical Carcinoma. Annals of Surgery, 2017, 265, 197-204.	4.2	38
87	T Cellâ€“ and Monocyte-Specific RNA-Sequencing Analysis in Septic and Nonseptic Critically Ill Patients and in Patients with Cancer. Journal of Immunology, 2019, 203, 1897-1908.	0.8	38
88	Defining the Role of Lymphadenectomy for Pancreatic Neuroendocrine Tumors: An Eight-Institution Study of 695 Patients from the US Neuroendocrine Tumor Study Group. Annals of Surgical Oncology, 2019, 26, 2517-2524.	1.5	38
89	Tumor-on-a-chip platform to interrogate the role of macrophages in tumor progression. Integrative Biology (United Kingdom), 2020, 12, 221-232.	1.3	37
90	Neutrophilâ€lymphocyte and plateletâ€lymphocyte ratio as predictors of disease specific survival after resection of adrenocortical carcinoma. Journal of Surgical Oncology, 2015, 112, 164-172.	1.7	36

#	Article	IF	Citations
91	Actual 10â€year survivors following resection of adrenocortical carcinoma. Journal of Surgical Oncology, 2016, 114, 971-976.	1.7	36
92	Whipple-specific complications result in prolonged length of stay not accounted for in ACS-NSQIP Surgical Risk Calculator. Hpb, 2017, 19, 147-153.	0.3	36
93	Nomogram predicting the risk of recurrence after curativeâ€intent resection of primary nonâ€metastatic gastrointestinal neuroendocrine tumors: An analysis of the U.S. Neuroendocrine Tumor Study Group. Journal of Surgical Oncology, 2018, 117, 868-878.	1.7	36
94	Adjuvant therapy is associated with improved survival after curative resection for hilar cholangiocarcinoma: A multiâ€institution analysis from the U.S. extrahepatic biliary malignancy consortium. Journal of Surgical Oncology, 2018, 117, 363-371.	1.7	36
95	New Nodal Staging for Primary Pancreatic Neuroendocrine Tumors. Annals of Surgery, 2019, Publish Ahead of Print, e28-e35.	4.2	36
96	Is Dedicated Research Time During Surgery Residency Associated With Surgeonsâ€™ Future Career Paths?. Annals of Surgery, 2020, 271, 590-597.	4.2	36
97	The importance of the proximal resection margin distance for proximal gastric adenocarcinoma: A multiâ€institutional study of the US Gastric Cancer Collaborative. Journal of Surgical Oncology, 2015, 112, 203-207.	1.7	35
98	Neuroendocrine liver metastasis: The chance to be cured after liver surgery. Journal of Surgical Oncology, 2017, 115, 687-695.	1.7	35
99	Pattern of Venous Collateral Development after Splenic Vein Occlusion in an Extended Whipple Procedure (Whipple at the Splenic Artery) and Long-Term Results. Journal of Gastrointestinal Surgery, 2017, 21, 516-526.	1.7	35
100	Repurposing Molecular Imaging and Sensing for Cancer Imageâ€“Guided Surgery. Journal of Nuclear Medicine, 2020, 61, 1113-1122.	5.0	35
101	The conundrum of < 2-cm pancreatic neuroendocrine tumors: AÂpreoperative risk score to predict lymph node metastases and guide surgical management. Surgery, 2019, 166, 15-21.	1.9	34
102	Actual 5-Year Survivors After Surgical Resection of Hilar Cholangiocarcinoma. Annals of Surgical Oncology, 2019, 26, 611-618.	1.5	34
103	Optimal extent of lymphadenectomy for gastric adenocarcinoma: A 7â€institution study of the U.S. gastric cancer collaborative. Journal of Surgical Oncology, 2016, 113, 750-755.	1.7	33
104	Is Linitis Plastica a Contraindication for Surgical Resection: A Multi-Institution Study of the U.S. Gastric Cancer Collaborative. Annals of Surgical Oncology, 2016, 23, 1203-1211.	1.5	33
105	Conditional probability of long-term survival after resection of hilar cholangiocarcinoma. Hpb, 2016, 18, 510-517.	0.3	33
106	Memory-like Differentiation Enhances NK Cell Responses to Melanoma. Clinical Cancer Research, 2021, 27, 4859-4869.	7.0	33
107	Neoadjuvant FOLFIRINOX Therapy Is Associated with Increased Effector T Cells and Reduced Suppressor Cells in Patients with Pancreatic Cancer. Clinical Cancer Research, 2021, 27, 6761-6771.	7.0	33
108	Multivisceral Resection for Gastric Cancer: Results from the US Gastric Cancer Collaborative. Annals of Surgical Oncology, 2015, 22, 840-847.	1.5	32

#	Article	IF	Citations
109	Oncologic effects of preoperative biliary drainage in resectable hilar cholangiocarcinoma: Percutaneous biliary drainage has no adverse effects on survival. Journal of Surgical Oncology, 2018, 117, 1267-1277.	1.7	32
110	A Comparison of Prognostic Schemes for Perihilar Cholangiocarcinoma. Journal of Gastrointestinal Surgery, 2016, 20, 1716-1724.	1.7	31
111	Assessing the impact of common bile duct resection in the surgical management of gallbladder cancer. Journal of Surgical Oncology, 2016, 114, 176-180.	1.7	30
112	Tumor budding in intestinal-type gastric adenocarcinoma is associated with nodal metastasis and recurrence. Human Pathology, 2017, 68, 26-33.	2.0	30
113	Gallbladder Cancer Presenting with Jaundice: Uniformly Fatal or Still Potentially Curable?. Journal of Gastrointestinal Surgery, 2017, 21, 1245-1253.	1.7	30
114	Association of preoperative monocyteâ€toâ€lymphocyte and neutrophilâ€toâ€lymphocyte ratio with recurrenceâ€free and overall survival after resection of pancreatic neuroendocrine tumors (USâ€NETSG). Journal of Surgical Oncology, 2019, 120, 632-638.	1.7	30
115	Association of Discharge Home with Home Health Care and 30-Day Readmission after Pancreatectomy. Journal of the American College of Surgeons, 2014, 219, 875-886e1.	0.5	29
116	The impact of caudate lobe resection on margin status and outcomes in patients with hilar cholangiocarcinoma: a multi-institutional analysis from the US Extrahepatic Biliary Malignancy Consortium. Surgery, 2018, 163, 726-731.	1.9	29
117	Minimally invasive versus open distal pancreatectomy for pancreatic neuroendocrine tumors: An analysis from the U.S. neuroendocrine tumor study group. Journal of Surgical Oncology, 2019, 120, 231-240.	1.7	29
118	Isotope tracing in adult zebrafish reveals alanine cycling between melanoma and liver. Cell Metabolism, 2021, 33, 1493-1504.e5.	16.2	29
119	The Prognostic Value of Signet-Ring Cell Histology in Resected Gastric Adenocarcinoma. Annals of Surgical Oncology, 2015, 22, 832-839.	1.5	28
120	To Roux or not to Roux: a comparison between Roux-en-Y and Billroth II reconstruction following partial gastrectomy for gastric cancer. Gastric Cancer, 2016, 19, 994-1001.	5.3	28
121	Routine portâ€site excision in incidentally discovered gallbladder cancer is not associated with improved survival: A multiâ€institution analysis from the US Extrahepatic Biliary Malignancy Consortium. Journal of Surgical Oncology, 2017, 115, 805-811.	1.7	28
122	Distal Cholangiocarcinoma and Pancreas Adenocarcinoma: Are They Really the Same Disease? A 13-Institution Study from the US Extrahepatic Biliary Malignancy Consortium and the Central Pancreas Consortium. Journal of the American College of Surgeons, 2017, 224, 406-413.	0.5	28
123	Comparison of 18F-FDG PET/CT and 111In Pentetreotide Scan for Detection of Merkel Cell Carcinoma. Clinical Nuclear Medicine, 2012, 37, 759-762.	1.3	27
124	Survival after resection of perihilar cholangiocarcinoma inÂpatients with lymph node metastases. Hpb, 2017, 19, 735-740.	0.3	27
125	Minimally Invasive Resection of Adrenocortical Carcinoma: a Multi-Institutional Study of 201 Patients. Journal of Gastrointestinal Surgery, 2017, 21, 352-362.	1.7	27
126	Outcomes after vascular resection during curative-intent resection for hilar cholangiocarcinoma: a multi-institution study from the US extrahepatic biliary malignancy consortium. Hpb, 2018, 20, 332-339.	0.3	27

#	Article	IF	Citations
127	Radiation therapy in the management of Merkel cell carcinoma: current perspectives. Expert Review of Dermatology, 2011, 6, 395-404.	0.3	26
128	An assessment of feeding jejunostomy tube placement at the time of resection for gastric adenocarcinoma: A sevenâ€institution analysis of 837 patients from the U.S. gastric cancer collaborative. Journal of Surgical Oncology, 2015, 112, 195-202.	1.7	26
129	Outcomes of Gastric Cancer Resection in Octogenarians: A Multi-institutional Study of the U.S. Gastric Cancer Collaborative. Annals of Surgical Oncology, 2015, 22, 4371-4379.	1.5	26
130	Stage-Specific Prognostic Effect of Race in Patients with Resectable Gastric Adenocarcinoma: An 8-Institution Study of the US Gastric Cancer Collaborative. Journal of the American College of Surgeons, 2016, 222, 633-643.	0.5	26
131	Role of radiation therapy for retroperitoneal sarcomas: An eightâ€institution study from the US Sarcoma Collaborative. Journal of Surgical Oncology, 2019, 120, 1227-1234.	1.7	26
132	ctDNA MRD Detection and Personalized Oncogenomic Analysis in Oligometastatic Colorectal Cancer From Plasma and Urine. JCO Precision Oncology, 2021, 5, 378-388.	3.0	26
133	Re-defining a high volume center for pancreaticoduodenectomy. Hpb, 2021, 23, 733-738.	0.3	26
134	A Study of Zoledronic Acid as Neo-Adjuvant, Perioperative Therapy in Patients with Resectable Pancreatic Ductal Adenocarcinoma. Journal of Cancer Therapy, 2013, 04, 797-803.	0.4	26
135	Relative purity of thrombin-based hemostatic agents used in surgery. Journal of the American College of Surgeons, 2003, 197, 580-590.	0.5	25
136	Operative Site Drainage after Hepatectomy: A Propensity Score Matched Analysis Using the American College of Surgeons NSQIP Targeted Hepatectomy Database. Journal of the American College of Surgeons, 2016, 223, 774-783e2.	0.5	25
137	Impact of lymph node ratio in selecting patients with resected gastric cancer for adjuvant therapy. Surgery, 2017, 162, 285-294.	1.9	25
138	Evaluating the American College of Surgeons National Surgical Quality Improvement project risk calculator: results from the U.S. Extrahepatic Biliary Malignancy Consortium. Hpb, 2017, 19, 1104-1111.	0.3	25
139	The impact of unplanned excisions of truncal/extremity soft tissue sarcomas: A multiâ€institutional propensity score analysis from the US Sarcoma Collaborative. Journal of Surgical Oncology, 2019, 120, 332-339.	1.7	25
140	Selective radiotherapy for the treatment of head and neck Merkel cell carcinoma. Cancer, 2012, 118, 3937-3944.	4.1	24
141	Clinical Score Predicting Long-Term Survival after Repeat Resection for Recurrent Adrenocortical Carcinoma. Journal of the American College of Surgeons, 2016, 223, 794-803.	0.5	24
142	Early Recurrence of Neuroendocrine Liver Metastasis After Curative Hepatectomy: Risk Factors, Prognosis, and Treatment. Journal of Gastrointestinal Surgery, 2017, 21, 1821-1830.	1.7	24
143	Survival benefit of lymphadenectomy for gallbladder cancer based on the therapeutic index: An analysis of the US extrahepatic biliary malignancy consortium. Journal of Surgical Oncology, 2020, 121, 503-510.	1.7	24
144	Evidence-Based Follow-up for the Patient with Melanoma. Surgical Oncology Clinics of North America, 2011, 20, 181-200.	1.5	23

#	Article	IF	Citations
145	Improved peri-operative outcomes with epidural analgesia in patients undergoing a pancreatectomy: a nationwide analysis. Hpb, 2015, 17, 551-558.	0.3	23
146	Preoperative Helicobacter pylori Infection is Associated with Increased Survival After Resection of Gastric Adenocarcinoma. Annals of Surgical Oncology, 2016, 23, 1225-1233.	1.5	23
147	Incidence and impact of Textbook Outcome among patients undergoing resection of pancreatic neuroendocrine tumors: Results of the US Neuroendocrine Tumor Study Group. Journal of Surgical Oncology, 2020, 121, 1201-1208.	1.7	23
148	Less is more in the difficult gallbladder: recent evolution of subtotal cholecystectomy in a single HPB unit. Surgical Endoscopy and Other Interventional Techniques, 2021, 35, 3249-3257.	2.4	23
149	Natural History of Preoperative Subcentimeter Pulmonary Nodules in Patients With Resectable Pancreatic Adenocarcinoma. Annals of Surgery, 2015, 261, 970-975.	4.2	22
150	Changing Odds of Survival Over Time among Patients Undergoing Surgical Resection of Gallbladder Carcinoma. Annals of Surgical Oncology, 2016, 23, 4401-4409.	1.5	22
151	Surgery Provides Long-Term Survival in Patients with Metastatic Neuroendocrine Tumors Undergoing Resection for Non-Hormonal Symptoms. Journal of Gastrointestinal Surgery, 2019, 23, 122-134.	1.7	22
152	Cost variation in a laparoscopic cholecystectomy and the association with outcomes across a single health system: implications for standardization and improved resource utilization. Hpb, 2015, 17, 1113-1118.	0.3	21
153	Proposal for Standardized Tabular Reporting of Observational Surgical Studies Illustrated in a Study on Primary Repair of Bile Duct Injuries. Journal of the American College of Surgeons, 2015, 221, 678-688.	0.5	21
154	Trends in the Number of Lymph Nodes Evaluated Among Patients with Pancreatic Neuroendocrine Tumors in the United States: A Multi-Institutional and National Database Analysis. Annals of Surgical Oncology, 2020, 27, 1203-1212.	1.5	21
155	Adjuvant therapy following resection of gastroenteropancreatic neuroendocrine tumors provides no recurrence or survival benefit. Journal of Surgical Oncology, 2020, 121, 1067-1073.	1.7	21
156	Defining and Predicting Early Recurrence after Resection for Gallbladder Cancer. Annals of Surgical Oncology, 2021, 28, 417-425.	1.5	21
157	Severe Nutritional Risk Predicts Decreased Long-Term Survival in Geriatric Patients Undergoing Pancreaticoduodenectomy for Benign Disease. Journal of the American College of Surgeons, 2014, 219, 1149-1156.	0.5	20
158	Impact of External-Beam Radiation Therapy on Outcomes Among Patients with Resected Gastric Cancer: A Multi-institutional Analysis. Annals of Surgical Oncology, 2014, 21, 3412-3421.	1.5	20
159	The Effects of Travel Burden on Outcomes After Resection of Extrahepatic Biliary Malignancies: Results from the US Extrahepatic Biliary Consortium. Journal of Gastrointestinal Surgery, 2017, 21, 2016-2024.	1.7	20
160	Duodenal neuroendocrine tumors: Impact of tumor size and total number of lymph nodes examined. Journal of Surgical Oncology, 2019, 120, 1302-1310.	1.7	20
161	In Patients with Localized and Resectable Gastric Cancer, What is the Optimal Extent of Lymph Node Dissectionâ€"D1 Versus D2 Versus D3?. Annals of Surgical Oncology, 2019, 26, 2912-2932.	1.5	20
162	Resection of pancreatic neuroendocrine tumors: defining patterns and time course of recurrence. Hpb, 2020, 22, 215-223.	0.3	20

#	Article	IF	Citations
163	Gene Therapy in Tissue-Engineered Blood Vessels. Tissue Engineering, 2003, 9, 1281-1287.	4.6	19
164	Flange Gastroenterostomy Results in Reduction in Delayed Gastric Emptying after Standard Pancreaticoduodenectomy: A Prospective Cohort Study. Journal of the American College of Surgeons, 2017, 225, 498-507.	0.5	19
165	Defining the Chance of Statistical Cure Among Patients with Extrahepatic Biliary Tract Cancer. World Journal of Surgery, 2017, 41, 224-231.	1.6	19
166	Prospective Evaluation of Pasireotide in Patients Undergoing Pancreaticoduodenectomy: The Washington University Experience. Journal of the American College of Surgeons, 2018, 226, 147-154e1.	0.5	19
167	Hepatic Resection for Non-functional Neuroendocrine Liver Metastasis: Does the Presence of Unresected Primary Tumor or Extrahepatic Metastatic Disease Matter?. Annals of Surgical Oncology, 2018, 25, 3928-3935.	1.5	19
168	Role of Additional Organ Resection in Adrenocortical Carcinoma: Analysis of 167 Patients from the U.S. Adrenocortical Carcinoma Database. Annals of Surgical Oncology, 2018, 25, 2308-2315.	1.5	19
169	Assessing the Role of Neoadjuvant Chemotherapy in Primary High-Risk Truncal/Extremity Soft Tissue Sarcomas: An Analysis of the Multi-institutional U.S. Sarcoma Collaborative. Annals of Surgical Oncology, 2019, 26, 3542-3549.	1.5	19
170	Association of Perioperative Transfusion with Recurrence and Survival After Resection of Distal Cholangiocarcinoma: A 10-Institution Study from the US Extrahepatic Biliary Malignancy Consortium. Annals of Surgical Oncology, 2019, 26, 1814-1823.	1.5	19
171	Analysis of textbook outcomes among patients undergoing resection of retroperitoneal sarcoma: A multiâ€institutional analysis of the US Sarcoma Collaborative. Journal of Surgical Oncology, 2020, 122, 1189-1198.	1.7	19
172	Defining the Risk of Early Recurrence Following Curative-Intent Resection for Distal Cholangiocarcinoma. Annals of Surgical Oncology, 2021, 28, 4205-4213.	1.5	19
173	Association Between Surgical Margins Larger Than 1 cm and Overall Survival in Patients With Merkel Cell Carcinoma. JAMA Dermatology, 2021, 157, 540.	4.1	19
174	Pathologic and Prognostic Implications of Incidental Nonincidental Gallbladder Cancer: A 10-Institution Study from the United States Extrahepatic Biliary Malignancy Consortium. American Surgeon, 2017, 83, 679-686.	0.8	19
175	Elevated Soluble CD30 Correlates with Development of Bronchiolitis Obliterans Syndrome Following Lung Transplantation. Transplantation, 2006, 82, 1596-1601.	1.0	18
176	Variations in Definition and Method of Retrieval of Complications Influence Outcomes Statistics after Pancreatoduodenectomy: Comparison of NSQIP with Non-NSQIP Methods. Journal of the American College of Surgeons, 2014, 219, 407-415.	0.5	18
177	Therapeutic index of lymphadenectomy among patients with pancreatic neuroendocrine tumors: A multiâ€institutional analysis. Journal of Surgical Oncology, 2019, 120, 1080-1086.	1.7	18
178	PLR and NLR Are Poor Predictors of Survival Outcomes in Sarcomas: A New Perspective From the USSC. Journal of Surgical Research, 2020, 251, 228-238.	1.6	18
179	Indications and outcomes of enucleation versus formal pancreatectomy for pancreatic neuroendocrine tumors. Hpb, 2021, 23, 413-421.	0.3	18
180	A Multi-institutional Analysis of Open Versus Minimally-Invasive Surgery for Gastric Adenocarcinoma: Results of the US Gastric Cancer Collaborative. Journal of Gastrointestinal Surgery, 2014, 18, 1563-1574.	1.7	17

#	Article	IF	Citations
181	Gastric remnant cancer: A distinct entity or simply another proximal gastric cancer?. Journal of Surgical Oncology, 2015, 112, 877-882.	1.7	17
182	Proposal for a new T-stage classification system for distal cholangiocarcinoma: a 10-institution study from the U.S. Extrahepatic Biliary Malignancy Consortium. Hpb, 2016, 18, 793-799.	0.3	17
183	Poor Reproducibility of Gallbladder Ejection Fraction by Biliary Scintigraphy for Diagnosis of Biliary Dyskinesia. Journal of the American College of Surgeons, 2018, 226, 155-159.	0.5	17
184	Biliary Injury After Laparoscopic Cholecystectomy in a Patient with Right Liver Agenesis: Case Report and Review of the Literature. Journal of Gastrointestinal Surgery, 2008, 12, 1577-1581.	1.7	16
185	Value of Peritoneal Drain Placement After Total Gastrectomy for Gastric Adenocarcinoma: A Multi-institutional Analysis from the US Gastric Cancer Collaborative. Annals of Surgical Oncology, 2015, 22, 888-897.	1.5	16
186	Assessing Trends in Palliative Surgery for Extrahepatic Biliary Malignancies: A 15-Year Multicenter Study. Journal of Gastrointestinal Surgery, 2016, 20, 1444-1452.	1.7	16
187	IL23 and TGF-ÃŸ diminish macrophage associated metastasis in pancreatic carcinoma. Scientific Reports, 2018, 8, 5808.	3.3	16
188	Timing of disease occurrence and hepatic resection on longâ€term outcome of patients with neuroendocrine liver metastasis. Journal of Surgical Oncology, 2018, 117, 171-181.	1.7	16
189	The role of radiation therapy and margin width in localized softâ€tissue sarcoma: Analysis from the US Sarcoma Collaborative. Journal of Surgical Oncology, 2019, 120, 325-331.	1.7	16
190	Influence of carcinoid syndrome on the clinical characteristics and outcomes of patients with gastroenteropancreatic neuroendocrine tumors undergoing operative resection. Surgery, 2019, 165, 657-663.	1.9	16
191	Advances in Modeling the Immune Microenvironment of Colorectal Cancer. Frontiers in Immunology, 2020, 11, 614300.	4.8	16
192	Incidence of Perioperative Complications Following Resection of Adrenocortical Carcinoma and Its Association with Longâ€Term Survival. World Journal of Surgery, 2016, 40, 706-714.	1.6	15
193	The diagnosis of pancreatic mucinous cystic neoplasm and associated adenocarcinoma in males: An eightâ€institution study of 349 patients over 15 years. Journal of Surgical Oncology, 2017, 115, 784-787.	1.7	15
194	The impact of extrahepatic disease among patients undergoing liverâ€directed therapy for neuroendocrine liver metastasis. Journal of Surgical Oncology, 2017, 116, 841-847.	1.7	15
195	A Novel T-Stage Classification System for Adrenocortical Carcinoma: Proposal from the US Adrenocortical Carcinoma Study Group. Annals of Surgical Oncology, 2018, 25, 520-527.	1.5	15
196	The importance of early recognition in management of ERCP-related perforations. Surgical Endoscopy and Other Interventional Techniques, 2018, 32, 4841-4849.	2.4	15
197	Predictive Value of Chromogranin A and a Pre-Operative Risk Score to Predict Recurrence After Resection of Pancreatic Neuroendocrine Tumors. Journal of Gastrointestinal Surgery, 2019, 23, 651-658.	1.7	15
198	Clinical relevance of performing endoscopic ultrasoundâ€guided fineâ€needle biopsy for pancreatic neuroendocrine tumors less than 2â€‰cm. Journal of Surgical Oncology, 2020, 122, 1393-1400.	1.7	15

#	Article	IF	Citations
199	Malignant Melanoma Arising at the Site of a Previously Excised Giant Congenital Melanocytic Nevus. JAMA Dermatology, 2014, 150, 100.	4.1	14
200	Readmission Following Gastric Cancer Resection: Risk Factors and Survival. Journal of Gastrointestinal Surgery, 2016, 20, 1284-1294.	1.7	14
201	Lung Surveillance Strategy for High-Grade Soft Tissue Sarcomas: Chest X-Ray or CT Scan?. Journal of the American College of Surgeons, 2019, 229, 449-457.	0.5	14
202	Studying a Rare Disease Using Multi-Institutional Research Collaborations vs Big Data: Where Lies the Truth?. Journal of the American College of Surgeons, 2018, 227, 357-366e3.	0.5	13
203	Tumor burden score predicts tumor recurrence of non-functional pancreatic neuroendocrine tumors after curative resection. Hpb, 2020, 22, 1149-1157.	0.3	13
204	Preclinical Evaluation of an Engineered Single-Chain Fragment Variable-Fragment Crystallizable Targeting Human CD44. Journal of Nuclear Medicine, 2021, 62, 137-143.	5.0	13
205	Development and Validation of a Modified Eighth AJCC Staging System for Primary Pancreatic Neuroendocrine Tumors. Annals of Surgery, 2022, 275, e773-e780.	4.2	13
206	Can the Risk of Non-home Discharge After Resection of Gastric Adenocarcinoma Be Predicted: a Seven-Institution Study of the US Gastric Cancer Collaborative. Journal of Gastrointestinal Surgery, 2015, 19, 207-216.	1.7	12
207	Surgical Site Infection Is Associated with Tumor Recurrence in Patients with Extrahepatic Biliary Malignancies. Journal of Gastrointestinal Surgery, 2017, 21, 1813-1820.	1.7	12
208	The Impact of Extent of Liver Resection Among Patients with Neuroendocrine Liver Metastasis: an International Multi-institutional Study. Journal of Gastrointestinal Surgery, 2019, 23, 484-491.	1.7	12
209	Staging laparoscopy among three subtypes of extraâ€hepatic biliary malignancy: a 15â€year experience from 10 institutions. Journal of Surgical Oncology, 2019, 119, 288-294.	1.7	12
210	Long-Term Outcomes after Spleen-Preserving Distal Pancreatectomy for Pancreatic Neuroendocrine Tumors: Results from the US Neuroendocrine Study Group. Neuroendocrinology, 2021, 111, 129-138.	2.5	12
211	The Effects of Perioperative Blood Transfusion on Morbidity and Mortality After Esophagectomy. Thoracic Surgery Clinics, 2006, 16, 75-86.	1.0	11
212	Predictors and Prognostic Implications of Perioperative Chemotherapy Completion in Gastric Cancer. Journal of Gastrointestinal Surgery, 2017, 21, 1984-1992.	1.7	11
213	Optimal extent of surgical and pathologic lymph node evaluation for resected intrahepatic cholangiocarcinoma. Hpb, 2018, 20, 470-476.	0.3	11
214	Accuracy of the ACS NSQIP Online Risk Calculator Depends on How You Look at It: Results from the United States Gastric Cancer Collaborative. American Surgeon, 2018, 84, 358-364.	0.8	11
215	Predictors of Disease-Free and Overall Survival in Retroperitoneal Sarcomas: A Modern 16-Year Multi-Institutional Study from the United States Sarcoma Collaboration (USSC). Sarcoma, 2019, 2019, 1-8.	1.3	11
216	Gastric carcinoids: Does type of surgery or tumor affect survival?. American Journal of Surgery, 2019, 217, 937-942.	1.8	11

#	Article	IF	Citations
217	Features of synchronous versus metachronous metastasectomy in adrenal cortical carcinoma: Analysis from the US adrenocortical carcinoma database. Surgery, 2020, 167, 352-357.	1.9	11
218	A 22-year experience with pancreatic resection for metastatic renal cell carcinoma. Hpb, 2020, 22, 312-317.	0.3	11
219	Cumulative GRAS Score as a Predictor of Survival After Resection for Adrenocortical Carcinoma: Analysis From the U.S. Adrenocortical Carcinoma Database. Annals of Surgical Oncology, 2021, 28, 6551-6561.	1.5	11
220	Care Fragmentation and Mortality in Readmission after Surgery for Hepatopancreatobiliary and Gastric Cancer: A Patient-Level and Hospital-Level Analysis of the Healthcare Cost and Utilization Project Administrative Database. Journal of the American College of Surgeons, 2021, 232, 921-932e12.	0.5	11
221	NCCN Guidelines Insights: Uveal Melanoma, Version 1.2019. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 120-131.	4.9	11
222	Clinical classification of symptomatic heterotopic pancreas of the stomach and duodenum: A case series and systematic literature review. World Journal of Gastroenterology, 2022, 28, 1455-1478.	3.3	11
223	Interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: long-term follow-up. Hpb, 2017, 19, 449-457.	0.3	10
224	Clinicopathologic score predicting lymph node metastasis in T1 gastric cancer. Surgery, 2018, 163, 889-893.	1.9	10
225	Association of perioperative transfusion with survival and recurrence after resection of gallbladder cancer: A 10â€institution study from the US Extrahepatic Biliary Malignancy Consortium. Journal of Surgical Oncology, 2018, 117, 1638-1647.	1.7	10
226	Interaction of race and pathology for neuroendocrine tumors: Epidemiology, natural history, or racial disparity?. Journal of Surgical Oncology, 2019, 120, 919-925.	1.7	10
227	Conditional diseaseâ€free survival after curativeâ€intent liver resection for neuroendocrine liver metastasis. Journal of Surgical Oncology, 2019, 120, 1087-1095.	1.7	10
228	Evaluating the ACS NSQIP Risk Calculator in Primary Pancreatic Neuroendocrine Tumor: Results from the US Neuroendocrine Tumor Study Group. Journal of Gastrointestinal Surgery, 2019, 23, 2225-2231.	1.7	10
229	Composite Length of Stay, An Outcome Measure of Postoperative and Readmission Length of Stays in Pancreatoduodenectomy. Journal of Gastrointestinal Surgery, 2020, 24, 2062-2069.	1.7	10
230	Is a Nomogram Able to Predict Postoperative Wound Complications in Localized Soft-tissue Sarcomas of the Extremity?. Clinical Orthopaedics and Related Research, 2020, 478, 550-559.	1.5	10
231	Predictors of Axillary Lymph Node Involvement in Women with T3 Breast Cancers: Analysis of 1988â€“2003 SEER Data. Journal of Surgical Research, 2010, 161, 183-189.	1.6	9
232	Neoadjuvant radiation improves marginâ€negative resection rates in extremity sarcoma but not survival. Journal of Surgical Oncology, 2020, 121, 1249-1258.	1.7	9
233	Renal Function After Retroperitoneal Sarcoma Resection with Nephrectomy: A Matched Analysis of the United States Sarcoma Collaborative Database. Annals of Surgical Oncology, 2021, 28, 1690-1696.	1.5	9
234	A multiâ€institutional validation study of prognostic nomograms for retroperitoneal sarcoma. Journal of Surgical Oncology, 2021, 124, 829-837.	1.7	9

#	Article	IF	Citations
235	Surgical treatment of gastric adenocarcinoma: Are we achieving textbook oncologic outcomes for our patients?. Journal of Surgical Oncology, 2022, 125, 621-630.	1.7	9
236	Establishment of Novel Neuroendocrine Carcinoma Patient-Derived Xenograft Models for Receptor Peptide-Targeted Therapy. Cancers, 2022, 14, 1910.	3.7	9
237	Cost benefit analysis of mesh reinforcement of stapled left pancreatectomy. Hpb, 2013, 15, 893-898.	0.3	8
238	Early recurrence of wellâ€differentiated (G1) neuroendocrine liver metastasis after curativeâ€intent surgery: Risk factors and outcome. Journal of Surgical Oncology, 2018, 118, 1096-1104.	1.7	8
239	Development of a Prognostic Nomogram and Nomogram Software Application Tool to Predict Overall Survival and Disease-Free Survival After Curative-Intent Gastrectomy for Gastric Cancer. Annals of Surgical Oncology, 2022, 29, 1220-1229.	1.5	8
240	Blood Transfusion and Survival for Resected Adrenocortical Carcinoma: A Study from the United States Adrenocortical Carcinoma Group. American Surgeon, 2017, 83, 761-768.	0.8	8
241	Surgeon Variation in Intraoperative Supply Cost for Pancreaticoduodenectomy: Is Intraoperative Supply Cost Associated with Outcomes?. Journal of the American College of Surgeons, 2018, 226, 37-45e1.	0.5	7
242	Evaluating the ACS-NSQIP Risk Calculator in Primary GI Neuroendocrine Tumor: Results from the United States Neuroendocrine Tumor Study Group. American Surgeon, 2019, 85, 1334-1340.	0.8	7
243	Outcomes of palliativeâ€intent surgery in retroperitoneal sarcomaâ€”Results from the US Sarcoma Collaborative. Journal of Surgical Oncology, 2020, 121, 1140-1147.	1.7	7
244	Identification of patients who may benefit the most from adjuvant chemotherapy following resection of incidental gallbladder carcinoma. Journal of Surgical Oncology, 2021, 123, 978-985.	1.7	7
245	Combined Systemic and Hepatic Artery Infusion Pump Chemo-Therapy as a Liver-Directed Therapy for Colorectal Liver Metastasis-Review of Literature and Case Discussion. Cancers, 2021, 13, 1283.	3.7	7
246	A novel preoperative risk score to guide patient selection for resection of soft tissue sarcoma lung metastases: An analysis from the United States Sarcoma Collaborative. Journal of Surgical Oncology, 2021, 124, 1477-1484.	1.7	7
247	Accuracy of the ACS NSQIP Online Risk Calculator Depends on How You Look at It: Results from the United States Gastric Cancer Collaborative. American Surgeon, 2018, 84, 358-364.	0.8	7
248	The impact of recent hospitalization on surgical site infection after a pancreatectomy. Hpb, 2015, 17, 819-823.	0.3	6
249	The prognostic significance of adrenocortical carcinomas identified incidentally. Journal of Surgical Oncology, 2018, 118, 1155-1162.	1.7	6
250	Outcomes of Elderly Patients Undergoing Curative Resection for Retroperitoneal Sarcomas: Analysis From the US Sarcoma Collaborative. Journal of Surgical Research, 2019, 233, 154-162.	1.6	6
251	Feasibility and safety of non-operative management of portal vein aneurysms: a thirty-five year experience. Hpb, 2021, 23, 127-133.	0.3	6
252	Identifying Risk Factors and Patterns for Early Recurrence of Pancreatic Neuroendocrine Tumors: A Multi-Institutional Study. Cancers, 2021, 13, 2242.	3.7	6

#	Article	IF	Citations
253	Are We Undertreating Black Patients with Nonfunctional Pancreatic Neuroendocrine Tumors? Critical Analysis of Current Surveillance Guidelines by Race. Journal of the American College of Surgeons, 2022, 234, 599-606.	0.5	6
254	Sublobar Resections for Lung Cancer. Seminars in Thoracic and Cardiovascular Surgery, 2006, 18, 85-91.	0.6	5
255	The impact of failure to achieve symptom control after resection of functional neuroendocrine tumors: An 8â€institution study from the US Neuroendocrine Tumor Study Group. Journal of Surgical Oncology, 2019, 119, 5-11.	1.7	5
256	Impact of perioperative blood transfusion on survival in pancreatic neuroendocrine tumor patients: analysis from the US Neuroendocrine Study Group. Hpb, 2020, 22, 1042-1050.	0.3	5
257	Appendiceal Neuroendocrine Tumors: Does Colon Resection Improve Outcomes?. Journal of Gastrointestinal Surgery, 2020, 24, 2121-2126.	1.7	5
258	Multidisciplinary Care of<scp>BRAF-Mutant</scp>Stage<scp>III</scp>Melanoma: A Physicians Perspective Review. Oncologist, 2021, 26, e1644-e1651.	3.7	5
259	Surgical Strategies for Bismuth Type I and II Hilar Cholangiocarcinoma: Impact on Long-Term Outcomes. Journal of Gastrointestinal Surgery, 2021, 25, 3084-3091.	1.7	5
260	ASO Visual Abstract: Development of a Prognostic Nomogram and Nomogram Software Application Tool to Predict Overall Survival and Disease-Free Survival After Curative-Intent Gastrectomy for Gastric Cancer. Annals of Surgical Oncology, 2021, 28, 734-735.	1.5	5
261	Extremity Soft Tissue Sarcoma: A Multi-Institutional Validation of Prognostic Nomograms. Annals of Surgical Oncology, 2022, , 1.	1.5	5
262	A New Operative Approach for Type I Choledochal Cysts. Journal of Gastrointestinal Surgery, 2014, 18, 1049-1053.	1.7	4
263	Metastatic melanoma after solid organ transplantation: An interdisciplinary, institution-based review of management with systemic and targeted therapies. Journal of the American Academy of Dermatology, 2018, 78, 184-185.	1.2	4
264	A novel, simplified, externally validated staging system for truncal/extremity soft tissue sarcomas: An analysis of the US Sarcoma Collaborative database. Journal of Surgical Oncology, 2018, 118, 1135-1141.	1.7	4
265	Retroperitoneal sarcoma perioperative risk stratification: A United States Sarcoma Collaborative evaluation of the ACSâ€NSQIP risk calculator. Journal of Surgical Oncology, 2020, 122, 795-802.	1.7	4
266	Impact of Insurance Status on Survival in Gastroenteropancreatic Neuroendocrine Tumors. Annals of Surgical Oncology, 2020, 27, 3147-3153.	1.5	4
267	Improved outcomes with minimally invasive pancreaticoduodenectomy in patients with dilated pancreatic ducts: a prospective study. Surgical Endoscopy and Other Interventional Techniques, 2022, 36, 3100-3109.	2.4	4
268	Malignant melanoma: evolving practice management in an era of increasingly effective systemic therapies. Current Problems in Surgery, 2022, 59, 101030.	1.1	4
269	Multi-institutional Development and External Validation of a Nomogram Predicting Recurrence After Curative Liver Resection for Neuroendocrine Liver Metastasis. Annals of Surgical Oncology, 2020, 27, 3717-3726.	1.5	4
270	Surgical Treatment of Neuroendocrine Tumors of the Terminal Ileum or Cecum: Ileocecectomy Versus Right Hemicolectomy. Journal of Gastrointestinal Surgery, 2022, 26, 1266-1274.	1.7	4

#	Article	IF	Citations
271	Surgical outcomes of gastroâ€enteroâ€pancreatic neuroendocrine tumors G3 versus neuroendocrine carcinoma. Journal of Surgical Oncology, 2022, 126, 689-697.	1.7	4
272	Reduction of Vascular Intimal-Medial Hyperplasia in Polytetrafluoroethylene Arteriovenous Grafts via Expression of an Inhibitor of G Protein Signaling. Annals of Vascular Surgery, 2005, 19, 712-718.	0.9	3
273	The Hand-Assisted Laparoscopic Approach to Resection of Pancreatic Mucinous Cystic Neoplasms: An Underused Technique?. American Surgeon, 2018, 84, 56-62.	0.8	3
274	Trends in the Use of Adjuvant Chemotherapy for High-Grade Truncal and Extremity Soft Tissue Sarcomas. Journal of Surgical Research, 2020, 245, 577-586.	1.6	3
275	Impact of resection margin on outcomes in highâ€grade soft tissue sarcomas of the extremityâ€”A USSC analysis. Journal of Surgical Oncology, 2021, 123, 479-488.	1.7	3
276	Inability to manage non-severe complications on an outpatient basis increases non-white patient readmission rates after pancreaticoduodenectomy: A large metropolitan tertiary care center experience. American Journal of Surgery, 2021, 222, 964-968.	1.8	3
277	A Case of a Pathological Complete Response to Neoadjuvant Nivolumab plus Ipilimumab in Periampullary Adenocarcinoma. Oncologist, 2021, 26, 722-726.	3.7	3
278	Anti-KRAS siRNA nanoparticles for targeted colorectal cancer therapy.. Journal of Clinical Oncology, 2017, 35, 636-636.	1.6	3
279	Evaluating the ACS-NSQIP Risk Calculator in Primary GI Neuroendocrine Tumor: Results from the United States Neuroendocrine Tumor Study Group. American Surgeon, 2019, 85, 1334-1340.	0.8	3
280	Inflammatory, insulin resistance metabolic markers and pancreatic cancer: quo vadis?. Future Oncology, 2014, 10, 1519-1522.	2.4	2
281	Incidence and Risk Factors Associated with Readmission After Surgical Treatment for Adrenocortical Carcinoma. Journal of Gastrointestinal Surgery, 2015, 19, 2154-2161.	1.7	2
282	A Multi-Institutional Study Comparing the Use of the American Joint Committee on Cancer 7th Edition Esophageal versus Gastric Staging System for Gastroesophageal Junction Cancer in a Western Population. American Surgeon, 2017, 83, 82-89.	0.8	2
283	Health-related quality of life in patients with malignant melanoma by stage and treatment status. Journal of the American Academy of Dermatology, 2021, 85, 486-489.	1.2	2
284	Perioperative chemotherapy is not associated with improved survival in high-grade truncal sarcoma. Journal of Surgical Research, 2018, 231, 248-256.	1.6	2
285	The safety of hepatectomy after transarterial radioembolization: Single institution experience and review of the literature. Journal of Surgical Oncology, 2020, 122, 1114-1121.	1.7	2
286	High neutrophil-lymphocyte ratio is not independently associated with worse survival or recurrence in patients with extremity soft tissue sarcoma. Surgery, 2020, 168, 760-767.	1.9	2
287	A closer look at the natural history and recurrence patterns of high-grade truncal/extremity leiomyosarcomas: A multi-institutional analysis from the US Sarcoma Collaborative. Surgical Oncology, 2020, 34, 292-297.	1.6	2
288	Specific Growth Rate as a Predictor of Survival in Pancreatic Neuroendocrine Tumors: A Multi-institutional Study from the United States Neuroendocrine Study Group. Annals of Surgical Oncology, 2020, 27, 3915-3923.	1.5	2

#	Article	IF	Citations
289	Recurrence of Nonâ€functional Pancreatic Neuroendocrine Tumors After Curative Resection: A Tumor Burdenâ€Based Prediction Model. World Journal of Surgery, 2021, 45, 2134-2141.	1.6	2
290	Semaphorin 4D Blockade Enhances T-Cell Penetration and Potentiates Response to Immune Checkpoint Blockade in a Murine Model of Pancreatic Cancer. Journal of the American College of Surgeons, 2021, 233, S252-S253.	0.5	2
291	Resection Status Does Not Impact Recurrence in Well-Differentiated Liposarcoma of the Extremity. American Surgeon, 2021, 87, 000313482110545.	0.8	2
292	Is a â€œMerkelâ€•Just Like a Melanoma? The Pathologic Analysis of Merkel Cell Carcinoma Specimens. Annals of Surgical Oncology, 2012, 19, 3304-3306.	1.5	1
293	Effects of Travel Burden on Outcomes after Resection of Extrahepatic Biliary Malignancies: Results from the US Extrahepatic Biliary Malignancy Consortium. Journal of the American College of Surgeons, 2016, 223, S144-S145.	0.5	1
294	Utility of Endoscopic Ultrasound in Evaluating Local RecurrenceÂAfter Surgery for Pancreatic Cancer. Clinical Gastroenterology and Hepatology, 2018, 16, 1834-1835.	4.4	1
295	Long term exocrine and endocrine function after pancreatectomy. Hpb, 2018, 20, S44-S45.	0.3	1
296	Surgical outcomes of patients with duodenal vs pancreatic neuroendocrine tumors following pancreatoduodenectomy. Journal of Surgical Oncology, 2020, 122, 442-449.	1.7	1
297	Enhanced recovery pathway after open pancreaticoduodenectomy reduces postoperative length of hospital stay without reducing composite length of stay. Hpb, 2021, , .	0.3	1
298	Retrospective analysis of circulating tumor DNA of archived plasma samples.. Journal of Clinical Oncology, 2016, 34, e23175-e23175.	1.6	1
299	Biomarker-Driven Prognostication in Merkel Cell Carcinoma: A Paradigm for Personalized Therapy. Annals of Surgical Oncology, 2021, , 1.	1.5	1
300	Laparoscopic resection of an intra-abdominal pulmonary sequestration. American Surgeon, 2010, 76, 778-80.	0.8	1
301	A Multi-Institutional Study Comparing the Use of the American Joint Committee on Cancer 7th Edition Esophageal Gastric Staging System for Gastroesophageal Junction Cancer in a Western Population. American Surgeon, 2017, 83, 82-89.	0.8	1
302	Oligometastatic Rectal Adenocarcinoma Treated With Short-Course Radiation Therapy and Chemotherapy With Nonoperative Intent of the Primary for Locoregional Complete Responders. Practical Radiation Oncology, 2022, 12, e406-e414.	2.1	1
303	Rates, Predictors, and Prognostic Implications of Perioperative Chemotherapy Completion in Gastric Cancer. Journal of the American College of Surgeons, 2016, 223, e186-e187.	0.5	0
304	Reply. Annals of Surgery, 2017, 266, e11.	4.2	0
305	Platelet-to-Lymphocyte and Neutrophil-to-Lymphocyte Ratios Are Poor Predictors of Survival Outcomes in Soft-Tissue Sarcomas: A New Perspective on Inflammatory Biomarkers from the USSC Database. Journal of the American College of Surgeons, 2018, 227, S247.	0.5	0
306	Utility of Intraoperative Margin Assessment by Frozen Section in Gastric Cancer. Annals of Surgical Oncology, 2019, 26, 3782-3783.	1.5	0

#	Article	IF	Citations
307	Infection Risk Stratification in Pancreatic Surgery: Look to the Blood. Journal of the American College of Surgeons, 2021, 232, 306-308.	0.5	0
308	In brief. Current Problems in Surgery, 2021, 59, 101032.	1.1	0
309	Demonstration of subpopulations with differing cancer stem cell phenotypes in xenograft and in vitro models of colorectal liver metastases.. Journal of Clinical Oncology, 2013, 31, 394-394.	1.6	0
310	The natural history of preoperative indeterminate pulmonary nodules in patients with resectable pancreatic adenocarcinoma.. Journal of Clinical Oncology, 2013, 31, 161-161.	1.6	0
311	Impact of external-beam radiation therapy on outcomes among patients with resected gastric cancer: A multi-institutional analysis.. Journal of Clinical Oncology, 2014, 32, 84-84.	1.6	0
312	Next-generation sequencing in pancreatic cancer: Novel mutations and potential targets for therapy.. Journal of Clinical Oncology, 2014, 32, e15228-e15228.	1.6	0
313	The effect of postoperative morbidity on long-term survival after curative resection for extra-hepatic biliary tumors: A multi-institution analysis from the U.S. Extrahepatic Biliary Malignancy Consortium.. Journal of Clinical Oncology, 2016, 34, 435-435.	1.6	0
314	Curative resection for hilar cholangiocarcinoma: Does adjuvant therapy impact overall survival? A multi-institution analysis from the U.S. Extrahepatic Biliary Malignancy Consortium.. Journal of Clinical Oncology, 2016, 34, 388-388.	1.6	0
315	Palliative treatment in extrahepatic biliary malignancies: A multi-institutional cohort.. Journal of Clinical Oncology, 2016, 34, 456-456.	1.6	0
316	A reappraisal of staging laparoscopy in three subtypes of cholangiocarcinoma: A multi-institution analysis from the U.S. Extrahepatic Biliary Malignancy Consortium.. Journal of Clinical Oncology, 2016, 34, 226-226.	1.6	0
317	Prospective phase I study of nab-paclitaxel plus gemcitabine with concurrent MR-guided IMRT in patients with locally advanced or borderline resectable pancreatic cancer.. Journal of Clinical Oncology, 2016, 34, TPS480-TPS480.	1.6	0
318	The optimal time-interval to re-resection for incidentally discovered gallbladder cancer: A multi-institution analysis from the US Extrahepatic Biliary Malignancy Consortium.. Journal of Clinical Oncology, 2016, 34, 201-201.	1.6	0
319	A multi-center study of 349 pancreatic mucinous cystic neoplasms: Preoperative risk factors for adenocarcinoma.. Journal of Clinical Oncology, 2016, 34, 231-231.	1.6	0
320	A novel pathology-based preoperative risk score to predict distant and locoregional residual disease and survival for incidentally discovered gallbladder cancer: A 10-institution study from the US Extrahepatic Biliary Malignancy Consortium.. Journal of Clinical Oncology, 2016, 34, 202-202.	1.6	0
321	Analysis of the effect of adjuvant therapy on overall survival for resected gallbladder adenocarcinoma using the National Cancer Database.. Journal of Clinical Oncology, 2017, 35, 360-360.	1.6	0
322	A novel t-stage classification system for adrenocortical carcinoma: Proposal from the U.S. Adrenocortical Carcinoma Study Group.. Journal of Clinical Oncology, 2017, 35, 266-266.	1.6	0
323	Effect of perioperative transfusion on recurrence and survival after resection of distal cholangiocarcinoma: A 10-institution study from the U.S. Extrahepatic Biliary Malignancy Consortium.. Journal of Clinical Oncology, 2017, 35, 236-236.	1.6	0
324	A Novel T-Stage Classification System for Adrenocortical Carcinoma: Proposal from the U.S. Adrenocortical Carcinoma Study Group. VideoEndocrinology, 2018, 5, .	0.1	0

#	Article	IF	Citations
325	Predictors of Desmoid Recurrence after Surgical Management from the US Sarcoma Collaborative. Journal of the American College of Surgeons, 2021, 233, S239-S240.	0.5	0
326	¹⁸Fâ€FDG positron emission tomographyâ€“computed tomographyÂhas a low positive predictive value for detecting occult recurrence in asymptomatic patients with highâ€risk Stages IIB, IIC, and IIIA melanoma. Journal of Surgical Oncology, 2022, 125, 525-534.	1.7	0
327	Thunderbeatâ„¢ Integrated Bipolar and Ultrasonic Forceps in the Whipple Procedure: A Prospective Randomized Trial. Missouri Medicine, 2020, 117, 559-562.	0.3	0
328	S0954â€ƒCompliance With ASGE Quality Indicators for Endoscopic Ultrasound Reports in the Evaluation of Pancreatic Cancer: Comparison of Community and Academic Practices. American Journal of Gastroenterology, 2020, 115, S488-S489.	0.4	0
329	ASO Visual Abstract: Extremity Soft Tissue Sarcomaâ€”A Multi-institutional Validation of Prognostic Nomograms. Annals of Surgical Oncology, 2022, 29, 3304.	1.5	0
330	DANSR: A Tool for the Detection of Annotated and Novel Small RNAs. Non-coding RNA, 2022, 8, 9.	2.6	0
331	Ramucirumab and irinotecan in patients with previously treated gastroesophageal adenocarcinoma: Final analysis of a phase II trial.. Journal of Clinical Oncology, 2022, 40, 284-284.	1.6	0
332	Incidentally discovered, intra-abdominal metallic foreign object on preoperative imaging. American Surgeon, 2010, 76, E180-1.	0.8	0
333	The Hand-Assisted Laparoscopic Approach to Resection of Pancreatic Mucinous Cystic Neoplasms: An Underused Technique?. American Surgeon, 2018, 84, 56-62.	0.8	0
334	Dynamic Prediction of Survival after Curative Resection of Gastric Adenocarcinoma: A landmarking-based analysis. European Journal of Surgical Oncology, 2021, , .	1.0	0
335	ASO Visual Abstract: Increased Morbidity and Mortality After Hepatectomy for Colorectal Liver Metastases in Frail Patients is Largely Driven by Worse Outcomes After Minor Hepatectomy: It is Not â€œJust a Wedgeâ€• Annals of Surgical Oncology, 2022, , 1.	1.5	0
336	Pollock: Fishing for Cell States. Bioinformatics Advances, 0, , .	2.4	0
337	Abstract 5333: Pancreatic cancer enhances HER2 signaling through DUSP6 to circumvent therapeutic MAPK inhibition. Cancer Research, 2022, 82, 5333-5333.	0.9	0